CHMP recommends higher dose of Novo Nordisk's Ozempic
The EMA's expert committee, the CHMP, has reported a positive opinion of Novo Nordisk's application to extend the marketing its diabetes drug Ozempic to a new dose of 2.0 mg.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN
A new version of Novo Nordisk's once-weekly diabetes drug Ozempic looks to be on the road to European patients, the pharmaceutical company reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Raising ambitions at Novo Nordisk an obvious move, says CEO
For subscribers
.jpg&w=384&q=75)
